{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"description":"Initiated a new ALK tyrosine kinase inhibitor for treatment of NSCLC following enrollment in the study","groups":[{"description":"Patients in this group signed consent, met eligibility criteria, and all had ALK-positive cancer of a primary lung lesion with systemic progression (excluding the central nervous system)","id":"OG000","title":"ALK-positive NSCLC With Progression"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients with at least 3 months of follow-up time","reportingStatus":"POSTED","timeFrame":"32 months","title":"Changed Treatment for NSCLC","type":"SECONDARY","unitOfMeasure":"Participants"}